ReviewLancet (London, England)2015
Rubella.
Review in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 4 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- Rubella antibody levels in the healthy Chinese population: a meta-analysis.Frontiers in immunology · 2024Pooled it
- Vaccines for measles, mumps, rubella, and varicella in children.The Cochrane database of systematic reviews · 2021Pooled it
- Vaccines for measles, mumps, rubella, and varicella in children.The Cochrane database of systematic reviews · 2020Pooled it
- Rubella Immunity in Pregnant Iranian Women: A Systematic Review and Meta-Analysis.International journal of fertility & sterility · 2019Pooled it
- Trial
- Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.Human vaccines & immunotherapeutics · 2017Trial
- Trends of congenital rubella syndrome among infants (0-11 months old) in India: a multicentre hospital-based sentinel surveillance (2016-2025).The Lancet regional health. Southeast Asia · 2026Article
- Target-Based Antiviral Drug Development Against Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2026Review
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- Article
- Evaluation of Commercial Immunoassays for Rubella Virus IgG Detection in Low-Antibody Sera Using a Recombinant Immunoblot as a Reference Method.Microorganisms · 2025Article
- Perception of Rubella and readiness to accept the vaccine among medical students in Enugu and Ebonyi States, Nigeria.BMC infectious diseases · 2025Article
- Rubella immunization policy in Japan: Immunity gaps arising from program differences and inconsistent cutoff standards.Human vaccines & immunotherapeutics · 2025Article
- Evaluation of toxoplasma, rubella, and cytomegalovirus seroprevalence and avidity testing in pregnant women.Pakistan journal of medical sciences · 2025Article
- Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose.Viruses · 2025Article
- Results of Cochlear Implantation in Patients with Congenital Rubell-Retrospective Study.Journal of clinical medicine · 2025Article
- Epidemiology of Rubella Virus in a Fragile and Conflict-affected Setting - A Retrospective Analysis of 11 Years Case-based Data in South Sudan.Open forum infectious diseases · 2025Article
- Rubella seroprevalence among women of childbearing age in Tunis, Tunisia.BMC infectious diseases · 2025Article
- Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population.Vaccines · 2025Article
- Ten-year surveillance and epidemiological patterns of measles and rubella: A study in the Babol County.Caspian journal of internal medicine · 2025Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Rubella remains an important pathogen worldwide, with roughly 100,000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.